
    
      Capecitabine, oxaliplatin and bevacizumab are well known active agents in the treatment of
      mCRC. The treatment of elderly patients with mCRC is an area of investigation. The role of
      comprehensive geriatric assessment in treatment efficacy and tolerance is an area of
      investigation.
    
  